Patients must have an estimated survival greater or equal to 3 months
Must have completed radiotherapy at least 12 months prior to entry
Child Pugh class A or B7 liver disease
Parent/caregiver and patient (if 12 years and older) must be willing to use a cellular telephone to receive medication reminders via text messaging during study period
Women who are postmenopausal by surgery, radiotherapy, or presence of natural amenorrhea >= 12 months
Patients must not be in status, coma, or assisted ventilation prior to study enrollment
Plan to treat with anastrozole for at least 12 months
Patients receiving sorafenib at the time of enrollment and those who are scheduled to receive sorafenib as part of a treatment plan are ineligible
Patients using prophylactic antimicrobial locks in the CVC at the time of enrollment and those who are scheduled to receive antimicrobial locks in the CVC as part of a treatment plan are ineligible
Patients must not receive metformin for at least 5 days prior to enrollment and for the duration of study treatment
Stratum 2: patients must have received radiation therapy, which may include gamma knife or phosphorus-32 (P32)* More than 6 months from the time of enrollment if the recurrence is predominantly solid* More than 12 months from the time of enrollment if the recurrence is predominantly cystic
Prior administration of anthracyclines is acceptable if therapy was completed > 6 months prior to study enrollment
Plan to be on chemotherapy or other allowable treatment for at least 3 months (minimum 70 days) and be willing to come in for study visits* The plan for treatment should be for at least 3 months at time of study enrollment; the treatment can stop earlier during the study at the discretion of the physician and patient (e.g., due to progression as noted through imaging, toxicity, or patient preference)
HCC patients only: Child Pugh class A or B7 liver disease
Angina pectoris =< 12 months prior to starting drug
Parts B1-B6, B8, D1-D6, E3, E4: patients must be >= 12 months and =< 30 years of age at the time of study enrollment
Young patient age between 12  15 could be included in only 6 centers (Bordeaux, Lyon, Villejuif, Lille, Marseille and Paris)
Presence of malignancy other than the study indication under this trial within 3 years of study enrollment
There should be no evidence for improvement in KS in the 3 months prior to study enrollment, unless there is evidence for progression of KS in the 4 weeks immediately prior to study enrollment
Patients must have completed study drug on arm 1 of A091401 (i.e., last dose of nivolumab) =< 12 months of re-registration to crossover dual agent therapy
Subjects with known hepatic insufficiency (i.e. Child-Pugh score A [mild], Child-Pugh score B [moderate] or Child-Pugh score C [severe]) according to Child-Pugh criteria
Relapse of pneumocystis carinii pneumonia within the past year before enrollment
Cirrhosis with Child-Pugh score of B or C
Patient must have completed cancer treatment >= 2 years prior to study enrollment
Patients with a BSA ? 1.17 m^2 at time of study enrollment are not eligible
Subjects may receive palliative radiotherapy for symptomatic metastases prior to enrollment provided that there is at least one other non-irradiated lesion amenable to LCT at the time of enrollment.
Infants must be > 36 weeks gestational age at the time of enrollment
Must have Child-Turcotte-Pugh (CTP) A or B7
>= 11 and < 25 years old at enrollment
